Diclofenac potassium for oral solution (CAMBIA®) in the acute management of a migraine attack: clinical evidence and practical experience
Sign Up to like & getrecommendations! Published in 2017 at "Therapeutic Advances in Neurological Disorders"
DOI: 10.1177/1756285616684494
Abstract: Migraine headache affects about 12% of Western populations and is the third most common disease worldwide (sixth in terms of disability). In 1993, triptans were introduced in the United States as a new treatment for… read more here.
Keywords: migraine; oral solution; potassium oral; diclofenac potassium ... See more keywords